United States-based Shepherd Therapeutics has collaborated with Mayo Clinic to advance research in rhabdomyosarcoma, a cancer that most often affects children, it was reported on Thursday.
Under the collaboration, both companies will use Shepherd Therapeutics' proprietary, next-generation precision-oncology platform, DELVE, to identify mechanisms for drug response and resistance in rhabdomyosarcoma (RMS) patients, and to identify new single drug and multi-drug combinations that have the potential to affect RMS care.
This RMS research project is being headed by the Mayo Clinic clinicians and scientists including Patricio Gargollo, MD, associate professor urology, paediatric urologist, Mayo Clinic, Candace Granberg, MD, assistant professor urology, paediatric urologist, Mayo Clinic and SHEPHERD Foundation Advisory Council member, and Fabrice Lucien-Matteoni, PhD, assistant professor of urology, Mayo Clinic.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval